Understanding paralogous epilepsy–associated GABAA receptor variants: Clinical implications, mechanisms, and potential pitfalls
Anthony S. H. Kan, Ali S. Kusay, Nazanin A. Mohammadi, Susan X. N. Lin, Vivian W. Y. Liao, Gaetan Lesca, Sabrine Souci, Mathieu Milh, Palle Christophersen, Mary Chebib, Rikke S. Møller, Nathan L. Absalom, Anders A. Jensen, Philip K. Ahring · 2024
Read Understanding paralogous epilepsy–associated GABAA receptor variants: Clinical implications, mechanisms, and potential pitfalls by Anthony S. H. Kan, Ali S. Kusay, Nazanin A. Mohammadi, Susan X. N. Lin, Vivian W. Y. Liao, Gaetan Lesca, Sabrine Souci, Mathieu Milh, Palle Christophersen, Mary Chebib, Rikke S. Møller, Nathan L. Absalom, Anders A. Jensen, Philip K. Ahring (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11648851.txt.
Introduction
Anthony Kan and a team of co-authors studied odd gene variants tied to epilepsy. Their paper, from twenty twenty-four, deals with receptors in the brain that calm nerve activity. Variants in the genes for these receptors can raise or cut their function. Some matched variants in kindred genes gave oddly distinct results. The team set out to learn why.
They built a group of eleven people who held matched variants in four such genes. They compared the traits and test results for each variant. Readers learn where the traps lie in reading these gene tests. The work helps labs judge what a variant means for a patient's care and risk.
Catalog record
| CREATOR | Anthony S. H. Kan, Ali S. Kusay, Nazanin A. Mohammadi, Susan X. N. Lin, Vivian W. Y. Liao, Gaetan Lesca, Sabrine Souci, Mathieu Milh, Palle Christophersen, Mary Chebib, Rikke S. Møller, Nathan L. Absalom, Anders A. Jensen, Philip K. Ahring |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Understanding paralogous epilepsy–associated GABAA receptor variants: Clinical implications, mechanisms, and potential pitfalls Authors: Anthony S. H. Kan, Ali S. Kusay, Nazanin A. Mohammadi, Susan X. N. Lin, Vivian W. Y. Liao, Gaetan Lesca, Sabrine Souci, Mathieu Milh, Palle Christophersen, Mary Chebib, Rikke S. Møller, Nathan L. Absalom, Anders A. Jensen, Philip K. Ahring Published: 2024 ABSTRACT SignificancePathogenic variants in γ-aminobutyric acid type A (GABAA)-receptor subunits are associated with severe developmental and epileptic encephalopathies. For the advancement of precision medicine, understanding both the pathogenicity and functional consequences of novel variants is crucial. To investigate whether insights from paralogous genes can serve as predictors, we studied a cohort of eleven individuals harboring paralogous missense variants in a conserved proline residue within the first transmembrane helix of GABAA receptor subunits. Despite diverse functional outcomes, all variants led to overall gain-of-function with increased GABA sensitivity being key to the clinical phenotype. Our findings support the use of information from paralogous variants in certain cases, but also highlight the importance of detailed functional characterization when assessing the molecular phenotypes of variants. γ-aminobutyric acid type A receptors (GABAARs) are members of the Cys-loop ligand-gated ion channel superfamily and comprise five subunits arranged in a pseudosymmetrical arrangement. The archetypical GABAAR subtypes consist of two α subunits, two β subunits and a single γ or δ subunit in a counterclockwise γ/δ-β-α-β-α arrangement (Fig. 1A) (1). Receptor subtypes can be assembled from six α (α1 to 6), three β (β1 to 3), three γ (γ1 to 3) subunits, and one δ subunit encoded by the genes GABRA1-6, GABRB1-3, GABRG1-3, and GABRD, respectively. The M1 proline residue is fully conserved in GABAAR subunits. (A) Top-Left: Cryo-EM structure of a pentameric GABAAR viewed from the extracellular side (PDB: 6HUP). Right: Cryo-EM structure of an α1 subunit viewed along the plasma membrane illustrating the M1 (purple) and M2 (teal) transmembrane domain (TMD) helices, and the position of the conserved M1 proline (red) and presumed pathogenic variants. ECD: extracellular domain; ICD: intracellular domain. (B) Amino acid sequence alignment of the M1 and M2 TMD helixes of α(1-5), β(1-3), γ(1-2), and δ subunits with the conserved proline bracketed in red. Based on a literature review, variants with published functional data are highlighted bold in yellow, with most of them located in fully (dark gray) or highly (light gray) conserved residues (2–16). Apart from GABRA6 and GABRG3, all major GABAAR genes have been clearly linked to neurodevelopmental disorders and epilepsy (17, 18). Genetic variants in GABAAR subunits are for example frequently observed in individuals with developmental and epileptic encephalopathies (DEE) (2). DEE encompasses a group of severe epilepsies characterized by seizures, interictal epileptiform activity on EEG, and encephalopathy, which involves significant developmental delay (DD) and cognitive impairment (19). Furthermore, recent studies have established clear correlations between functional and clinical outcomes for these variants (3–5). For example, individuals with gain-of-function (GOF) variants typically present with more severe clinical phenotypes than those with loss-of-function (LOF) variants. Importantly, the functional outcome of a variant may have implications for whether antiseizure medications that enhance GABAergic neurotransmission should be used or avoided (6). Moreover, the recent approval of antisense oligonucleotides (ASOs) for certain rare diseases, such as spinal muscular atrophy, marks an interesting new advancement. ASOs, tailored to up-regulate or down-regulate the expression of mutated GABAAR subunit mRNAs, could potentially present disease-modifying interventions. Hence, regardless of the intervention type, it is crucial to know whether variants are GOF or LOF, yet such information is rarely available for newly identified variants. GABAAR subunits exhibit significant overall sequence identity, ranging from 34 to 87%, and novel variants typically appear in conserved positions, where the amino acid identity can be up to 100% across all subunits. For instance, pathogenic variants are enriched at transmembrane helices (M1-M4), which form the receptor’s ion channel pore (1). Yet, even in these highly conserved regions, functional information is only available for a limited number of variants, scattered among the different subunits (Fig. 1B). Therefore, exploring alternative avenues to gather information regarding functional outcomes is essential. Within the ion channel field, it is generally assumed that variants at identical amino acid positions in closely related genes will likely yield similar functional effects. In fact, pathogenicity prediction databases incorporate information of homologous variants in paralogous genes (hereafter termed paralogous variants), when functional data for a specific variant are unavailable [e.g., the AlphaMissense prediction tool (20)]. This approach has successfully been used to predict functional changes at sodium and calcium channels (21, 22). Based on such success, it has even been suggested recently that paralogous variant information could be used for applying the ACMG PS1/PM5 criteria to novel variants (23). Unlike sodium or potassium channels and other gene families, the individual subunits in GABAARs are not functionally equivalent. Instead, the pseudosymmetrical receptor structure has evolved to include subunit-specific functional regions with distinct roles in channel function. This is evident in the extracellular region, where GABA-binding sites are located on different sides of the α and β subunits. In contrast, the transmembrane pore-forming regions are expected to display higher functional equivalence across subunit types. Therefore, it is most meaningful to compare variants in regions of high functional equivalence. Some studies support the notion that paralogous variants in transmembrane regions can have similar functional effects. For instance, pathogenic variants affecting a fully conserved threonine residue in the M2 helix of GABRA4, GABRB3, and GABRD all result in a GOF molecular phenotype (5, 7, 8). However, observations for a similarly conserved proline residue in the center of the M1 transmembrane helix are conflicting (Fig. 1 A and B). Variants of this M1 proline have been identified across all major subunit types (8–11, 24–28), yet functional analyses revealed surprisingly diverse outcomes spanning from LOF traits [GABRA1, GABRB2, and GABRG2 variants (9–11)] over limited functional changes [GABRB3 variant (5)] to GOF traits [GABRD (8)]. Thus, a clear understanding of the utility of paralogous variants in GABAARs remains elusive. The proposed use of information from paralogous variants to apply the ACMG criteria highlights the need to assess whether functional data supports such use, and whether the literature provides dependable sources for functional outcomes. Given the pseudosymmetrical nature of GABAAR assembly, variants in the M1 proline are particularly suitable for this study. These variants exist in many different subunit types and the reported functional data for them are conflicting. Therefore, we tested the hypothesis that paralogous variants at the M1 proline of subunits that assemble into the major synaptic α1β2/3γ2 GABAAR subtypes lead to similar functional outcomes and comparable clinical phenotypes. Results We collected a cohort of 11 individuals with DEE due to seven different de novo M1 proline variants in GABRA1, GABRB2, GABRB3, or GABRG2 encoding the α1, β2, β3, or γ2 subunits, respectively (Fig. 1A). Summaries of electroclinical data are presented in Fig. 2 and SI Appendix, Fig. S1, while full information is available in Dataset S1. Clinical features of individuals with M1 proline variants in GABRA1, GABRB2, GABRB3, and GABRG2. (A) Distribution of age of seizure onset, epileptic syndromes, and eight key clinical features in the M1 proline cohort are shown. Solid line and dotted lines in the violin plot depict the median and interquartile range, respectively. EIDEE: Early infantile developmental and epileptic encephalopathy;